84 results about "Enteric coated tablets" patented technology

The invention discloses an atorvaquone enteric-coated tablet, the preparation comprises atorvaquone, glyceryl behenate, teloxpol, a filler, an adhesive, a disintegrating agent and an enteric coating, and the particle size D90 of the atorvaquone is 30-50 [mu] m. The atorvaquone enteric-coated tablet disclosed by the invention is stable and continuous in release and high in bioavailability, can be positioned and released in intestinal tracts and reduce liver circulation, so that the occurrence of phenomena such as liver injury is reduced, the phenomena such as sticking and cracking are avoided in a tabletting process, the quality is qualified and stable, and the dissolution performance and the stability of the atorvaquone enteric-coated tablet are also ensured.

The doxylamine succinate pyridoxine enteric-coated tablet comprises a tablet core and a coating layer, the coating layer comprises a first isolation layer, an enteric-coated layer and a second isolation layer, the materials of the enteric-coated layer comprise a plasticizer, an anti-sticking agent, a defoaming agent and a flexible coating material, and the flexible coating material accounts for 24-28% of the mass of the tablet core. By adding the flexible coating material, the stability of the pharmaceutical preparation is improved, the difference between batches is reduced, the drug dissolution rate reaches 90% or above, and the pharmaceutical preparation can be quickly released.

The invention relates to the technical field of biological medicine, in particular to an ilaprazole enteric-coated tablet and a preparation method thereof. The ilaprazole enteric-coated tablet sequentially comprises a tablet core, an isolating layer and an enteric-coated layer from inside to outside, the tablet core at least comprises an active ingredient ilaprazole or a pharmaceutically acceptable salt thereof, the particle size D90 of the ilaprazole or the pharmaceutically acceptable salt thereof is less than or equal to 10 microns, and a solvent used in a coating process of the isolating layer is water. By controlling the particle size D90 of the ilaprazole to be less than or equal to 10 microns and controlling the preparation method of the tablet core, the tablet core with relatively good content uniformity and appearance state is prepared, the problem that the tablet core is easy to generate spots is solved, and the problem that the intestinal tract is stimulated by over-high local drug concentration when the ilaprazole enteric-coated tablet is released and dissolved out is avoided. In the coating process of the isolating layer, solvent purified water is used for replacing traditional ethanol, so that the problems of pressure for removing an organic solvent in the preparation process of the tablet and environmental pollution in the preparation process are avoided under the condition of ensuring the quality of the tablet.

The invention belongs to the technical field of proton pump inhibition medicine preparations, and relates to a rabeprazole sodium enteric-coated tablet and a preparation method thereof. The technical problems that an existing rabeprazole sodium enteric-coated tablet is insufficient in stability, lagged in dissolution and the like are solved. The enteric-coated tablet consists of a tablet core and an enteric-coated coating layer wrapped outside the tablet core, wherein the tablet core comprises auxiliary materials such as rabeprazole sodium, a filling agent, an adhesive, a stable dissolution promoter and the like; the enteric coating layer comprises an enteric coating material, a plasticizer, an anti-sticking agent and a solvent. Through the synergistic effect of the compound stabilizer and process control, the stability and dissolution performance of the enteric-coated tablet are synergistically improved, meanwhile, the production process is simplified, and the preparation method is suitable for industrial application.

The invention provides a bromocriptine mesylate enteric-coated tablet and a preparation method thereof. Specifically, the bromocriptine mesylate enteric-coated tablet comprises a tablet core and an enteric coating layer wrapping the tablet core. The enteric-coated tablet disclosed by the invention is simple in process, good in stability and small in gastrointestinal side effect, the bioavailability of the enteric-coated tablet is more than two times that of a common tablet sold in the market, the dosage is expected to be reduced, the side effect is further reduced, and the enteric-coated tablet has excellent clinical value.

1. The name of the design product: packaging box (omeprazole enteric-coated tablets). 2. The use of the design product: used for the outer packaging of products. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: the unfolded state reference drawing.

This utility model relates to the technical field of coating devices, specifically a coating device for the enteric coating layer of bisacodyl enteric-coated tablets. It includes a cabinet with a roller inside. A rotating ring is connected to the left side wall of the cabinet, and the left end of the rotating ring is rotatably connected to the inner left side wall of the cabinet via a bearing. In operation, bisacodyl tablets are placed into the roller, the door is closed, and a motor drives the drive wheel, transmission belt, driven wheel, rotating ring, and roller to rotate. Support rollers provide support and improve the stability of the roller's rotation. A peristaltic pump draws and delivers the coating solution to the nozzle of a spray gun. The spray gun is connected to a compressed air pipeline, and the compressed air is used to evenly spray the coating solution onto the surface of the bisacodyl tablets for coating. The rotation of the roller causes the tablets to continuously rotate, ensuring the uniformity of the coating solution spray, thereby effectively coating the surface of the bisacodyl tablets with an enteric coating layer.

The invention discloses an artemisia selengensis leaf extract self-microemulsifying drug delivery system and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The system is composed of artemisia selengensis leaf extract and a self-microemulsion drug delivery system composed of an oil phase, a surfactant and a cosurfactant, and the mass ratio of the oil phase to the surfactant to the cosurfactant is (10-20): (60-80): (10-30). According to the invention, the liquid system is solidified into powder through an adsorption carrier, and the powder is further prepared into enteric-coated tablets. The drug delivery system can significantly improve the solubility, stability and intestinal absorption efficiency of caffeoylquinic acid compounds (CQAs) in the artemisia selengensis leaves, effectively inhibits degradation of the caffeoylquinic acid compounds in gastric juice, shows excellent xanthine oxidase inhibitory activity, can be used for preparing functional foods or drugs for reducing uric acid, and realizes high-valued utilization of artemisia selengensis leaf resources.

The invention discloses a galanthamine hydrobromide enteric-coated tablet and a preparation method thereof. The tablet is composed of a tablet core, an isolation layer and an enteric layer, the tablet core contains 5.0%-16.0% of galanthamine hydrobromide, and auxiliary materials such as mannitol, a mixture of magnesium stearate and sodium stearyl fumarate in a specific proportion, colloidal silicon dioxide and the like are matched; the isolating layer adopts an opadry II type film coating, and the enteric-coated layer adopts an opadry Acryl-EZE II type enteric-coated coating. The dissolution rate of the tablet in an acidic medium with the pH value of 1.2 for 2 hours is less than 5%, the release rate of the tablet in a medium with the pH value of 5.5 or 6.8 for 45 minutes is more than or equal to 80%, the tablet is sealed and placed at 40 DEG C + / -2 DEG C / 75% + / -5% RH for 6 months, the stability is good, and the pharmacokinetic parameters are excellent. The preparation method comprises the steps of raw and auxiliary material pretreatment, graded premixing, total mixing and lubricating, tabletting, two-step coating and the like, and the process is stable and controllable. The enteric-coated tablet disclosed by the invention is strong in targeted release property, high in stability and good in bioavailability, and can guarantee the effectiveness and safety of medication.

The invention provides a method for separating and detecting components in butanedisulfonic acid ademetionine enteric-coated tablets, and belongs to the technical field of medicine quality analysis. According to the method, ammonium formate solution-water-acetonitrile and ammonium formate solution-acetonitrile-methyl tert-butyl ether are used as a mobile phase system, and the pH value of the ammonium formate solution is controlled to be 2.2-3.1, so that adenosine and adenine can be effectively separated; according to the method, the S-adenosyl-L-methionine glycine isomer 2, adenosine, adenine and S-adenosyl-L-homocysteine can be separated, the time consumption is short, the separation efficiency is high, the operation is simple, the separation cost is low, and the quality control of butanedisulfonic acid adenosyl methionine or related preparations can be improved. According to the method, the detection of the ademetionine and the related impurities is not influenced by auxiliary materials, the method is efficient and convenient, good in reproducibility, high in specificity, high in accuracy and high in sensitivity, and the quality control of the ademetionine sample can be realized.

The invention discloses an in-vitro dissolution method of a posaconazole enteric-coated tablet, which is characterized in that a Tween-80 (TWEEN-80) surfactant is added into a dissolution medium, so that the solubility of the posaconazole enteric-coated tablet in a phosphate buffer solution is remarkably improved, the phenomenon that a solution in a dissolution cup is not uniform is solved, the jump point phenomenon of a dissolution curve is eliminated, and the dissolution rate of the posaconazole enteric-coated tablet is improved. When a phosphate buffer solution added with a certain amount of surfactant is used as a dissolution medium, the accumulated dissolution amount at each time point is stable, the dissolution curve is smooth, the detection result is accurate and reliable, the repeatability and predictability of the dissolution test are remarkably improved, and a more reliable detection method is provided for the initial stage of drug research and development and quality control.

The present invention relates to a tablet press discharging device and a preparation process for diclofenac sodium enteric-coated tablets. The tablet press discharging device comprises: a discharging slot is provided with a feed port and a discharging port, the bottom of the slot is inclined downward along the discharging direction, the discharging slot pivots at least three springs that rotate between a first position and a second position, the springs are interlaced and divide the discharging slot into a primary division chamber and at least two subdivision chambers along the discharging direction, the slot bottoms of the primary division chamber and the subdivision chamber are both provided with a group of sieve holes, the diameter of the sieve holes is smaller than the diameter of the tablets, and the springs are arranged on one side of each group of sieve holes close to the discharging port; the dust collecting mechanism corresponds to the sieve holes, including a powder collecting box and a dust collector, the powder collecting box is arranged below the sieve holes, and the dust collector is connected to the powder collecting box through a pipeline; when the spring is in the first position, the tablets are intercepted by the spring; when the spring is in the second position, the tablets are released and slide toward the discharging port. The discharging device of the present invention can timely and effectively remove the drug powder so that the tablet coating effect is highly uniform.

The invention discloses a progesterone enteric-coated tablet processing technology. The technology comprises the following steps: 1, preparing a tablet core; 2, coating an isolating layer; 3, coating an enteric-coated layer; and 4, coloring layer coating. According to the processing technology of the progesterone enteric-coated tablet, the overall technological steps, technological parameters in all the technological steps and the raw material formula are optimized, the steps are simple, operation is easy, the quality of all layers of coatings can be effectively controlled, the stability and consistency of the final product are ensured, the prepared progesterone enteric-coated tablet can stably release medicine in the intestinal tract, and the bioavailability of the product is improved. The absorption speed is high, and the medication comfort and compliance of a patient are improved, so that the requirements of clinical treatment are better met.

This application provides a pharmaceutical composition comprising: an active ingredient, a filler, a disintegrant, and optionally one or more of a binder, a flow aid, and a lubricant. It also provides an enteric-coated tablet comprising (1) a core containing the aforementioned pharmaceutical composition; (2) an optional insulating layer; and (3) an enteric coating layer. The active ingredient in the enteric-coated tablet is not released in the stomach but is released in the intestines, preventing the active ingredient in the composition from degrading in the acidic environment of the stomach.

The utility model provides an air heater for enteric-coated tablet coating production, which comprises an air supply mechanism, a heating mechanism and a temperature adjusting tank, and the air outlet end of the air supply mechanism is connected with the temperature adjusting tank through a first connecting pipe. The heating mechanism is connected with the gas outlet end of the gas supply mechanism through a second connecting pipe, the heating mechanism is connected with the temperature adjusting tank through a third connecting pipe, and a gas distribution mechanism is installed on the temperature adjusting tank. By arranging the electromagnetic heating assembly and the net type heating mechanism, air fed into the net type heating mechanism by the air supply mechanism can be rapidly heated to a required temperature through the electromagnetic heating assembly during use, so that hot air can be timely supplied to a drying system for use; and meanwhile, the electromagnetic heating mode is adopted, so that the energy utilization rate can be increased, energy consumption is reduced, and the electricity utilization cost needed by air heating is reduced.

The present invention discloses an atovaquone enteric-coated tablet, which preparation comprises atovaquone, glyceryl behenate, tyloxapol, a filler, a binder, a disintegrant and an enteric coating, and the particle size D90 of atovaquone is 30-50 μm. The atovaquone enteric-coated tablet of the present invention has a stable and continuous release, high bioavailability, can be released at a specific position in the intestine, reduce the hepatic circulation, thereby reducing the occurrence of phenomena such as liver injury, and has no phenomena such as sticking to the punch and capping during the tabletting process, with qualified and stable quality, and ensures its dissolution performance and stability.

This utility model belongs to the field of pharmaceutical machinery technology, specifically relating to a coating device for the sugar coating layer of bisacodyl enteric-coated tablets. It includes a base and a coating pan. A frame is fixedly mounted on the base, and control buttons are located outside the frame. A blower is located inside the frame, and an air duct is fixedly mounted on the frame, communicating with the blower. A tilting and adjustable safety component is provided between the base, frame, and coating pan. This utility model, through corresponding structural improvements, utilizes a worm gear and worm design to enable rapid angle tilting of the coating pan, facilitating feeding by the operator. The design of the arc-shaped through-hole, telescopic rod, and pin allows for positioning at the feeding and rotation positions, reducing the burden on the worm gear and extending the overall service life. Heating by a heating device ensures a uniform sugar coating thickness, preventing the coated tablets from becoming too wet and improving coating efficiency.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a diclofenac sodium enteric-coated tablet and a preparation method thereof. The diclofenac sodium enteric-coated tablet comprises a quick-release layer, a slow-release layer and an enteric-coated layer; the quick-release layer comprises the following components in parts by weight: 20-40 parts of diclofenac sodium, 5-15 parts of a disintegrating agent, 20-50 parts of a filling agent, 1-3 parts of a lubricant and 1-5 parts of a binder; the slow-release layer comprises the following components in parts by weight: 50-80 parts of diclofenac sodium, 5-15 parts of crosslinked chitosan, 1-3 parts of a lubricant and 1-5 parts of a binder; and the enteric-coated layer comprises the following components in parts by weight: 20-45 parts of an enteric material and 5-15 parts of N-acetylneuraminic acid derivative. The diclofenac sodium enteric-coated tablet has excellent in-vitro cumulative release degree, and has low hygroscopicity, high stability and high friability.

The utility model discloses a packaging processing device for enteric-coated tablet production, and relates to the technical field of medicine production. The device comprises a belt type conveying device, a plurality of supporting legs are installed at the bottom of the belt type conveying device, a plurality of supports are installed at the top of the belt type conveying device, a material storage box is installed at the tops of the supports, a discharging pipe is installed at the bottom of the material storage box, and a piece adding cylinder is fixedly connected to the bottom of the discharging pipe. Two tablet plates are arranged at the top of the belt type conveying device, and the positioning part is installed in the belt type conveying device. According to the utility model, the positioning part is arranged, specifically, the motor is started to drive the two-way threaded rod to rotate clockwise, so that the two movable frames and the positioning plates on the outer surface of the two-way threaded rod are close to each other, the motor is closed after the width of the tablet plate is adjusted to a proper position, and the right sides of the two positioning plates are V-shaped, so that the tablet plate can be guided to enter between the two positioning plates to be aligned with the tablet adding cylinder; and the mode can flexibly adapt to tablet plates with different widths, so that the applicability is improved.

A metformin hydrochloride enteric-coated tablet, which consists of a tablet core containing a therapeutically effective amount of metformin hydrochloride and an enteric coating layer wrapping the tablet core, and has a metformin hydrochloride dissolution of not higher than 15% within 2 hours in a pH 4.5 medium and a metformin hydrochloride dissolution of not less than 85% within 20 minutes in a pH 6.8 medium. The metformin hydrochloride enteric-coated tablet, which meets specific drug release technical requirements, is obtained by means of selecting the disintegration time limit of the tablet core, the dissolution point of the enteric coating material and the weight gain of the coating. Compared with common preparations of metformin hydrochloride (such as glucophage) and enteric-coated tablets having other release characteristics, the metformin hydrochloride enteric-coated tablet improves the tolerance and compliance of metformin hydrochloride without reducing the hypoglycemic efficacy.

The invention provides an erythromycin enteric-coated tablet and a preparation method thereof, and relates to the technical field of erythromycin medicine preparation. The erythromycin enteric-coated tablet is prepared from erythromycin, corn starch, modified corn starch, carboxymethyl starch sodium, sodium dodecyl sulfate, magnesium stearate, cane sugar, ethanol, polyacrylic resin II, polyacrylic resin III and edible triethyl citrate. The defects in the prior art are overcome, the stability of the erythromycin enteric-coated tablet in gastric acid and the disintegration efficiency of the erythromycin enteric-coated tablet in intestinal juice are effectively improved, and the quality and the curative effect of the medicine are comprehensively improved.

The present invention relates to the unexpected discovery that the oral administration of charged sodium channel blockers (also known as "Nocions") alleviates inflammation in intestinal inflammatory diseases, such as inflammatory bowel disease (IBD), ulcerative colitis and / or Crohn's disease, without substantial systemic exposure, as proved by low plasma concentrations. The formulations are designed as enteric-coated tablets to release the composition at selected locations of the intestinal tract.

The application provides a method for separating and detecting ingredients in a butanedisulfonic acid ademetionine enteric-coated tablet, and belongs to the technical field of drug quality analysis. The application uses ammonium formate solution-water-acetonitrile and ammonium formate solution-acetonitrile-methyl tert-butyl ether as a mobile phase system, and controls the pH value of the ammonium formate solution to be 2.2-3.1, so that adenosine and adenine can be effectively separated, and ademetionine, decarboxylated ademetionine, S-adenosyl-L-methionine glycine isomer 2, adenosine, adenine and S-adenosyl-L-homocysteine can be highly separated at one time, the method has the advantages of short time consumption, high separation efficiency, simple operation, low separation cost, and is favorable for improving the quality control of butanedisulfonic acid ademetionine or related preparations. In the application, the detection of ademetionine and related impurities is not affected by excipients, and has the advantages of high efficiency, convenience, good reproducibility, strong specificity, high accuracy and high sensitivity, and can realize the quality control of ademetionine samples.

This invention discloses a traditional Chinese medicine composition for treating ulcerative colitis, its preparation method, combined drugs, and applications. The traditional Chinese medicine composition for treating ulcerative colitis of this invention is made from the following raw materials in parts by weight: Astragalus membranaceus 13-26 parts, Lonicera japonica 10-20 parts, Sargentodoxa cuneata 10-20 parts, Prunus mume 8-16 parts, Agrimonia pilosa 8-16 parts, Allium macrostemon 6-12 parts, Platycodon grandiflorus 6-12 parts, Coptis chinensis 3-6 parts, and Panax notoginseng powder 1-3 parts. An animal model of ulcerative colitis was constructed using DSS induction, and the results showed that the traditional Chinese medicine composition of this invention has a certain therapeutic effect on ulcerative colitis. Clinical studies showed that the traditional Chinese medicine composition of this invention, used in combination with mesalazine enteric-coated tablets, can reduce the modified Mayo score and serum inflammatory markers in patients with active ulcerative colitis, improve colonic mucosal inflammation and gastrointestinal symptoms, and effectively treat active ulcerative colitis of the damp-heat type.

1.The name of the design product: packaging box (alengling aspirin enteric-coated tablets). 2.The use of the design product: used for the outer packaging of medicines. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: front view. 5.The design contains colors.

The present invention provides a dimethyl fumarate enteric-coated tablet, which includes a dimethyl fumarate tablet, an isolation layer and an enteric layer from the inside to the outside, and the coating material for the isolation layer is a mixture of hydroxypropyl cellulose, methacrylic acid-methyl methacrylate copolymer 1:1, talcum powder, and triethyl citrate in a mass ratio of 5-8:2-4:0.5-1.5:0.5-1.5, wherein the weight-average molecular weight of hydroxypropyl cellulose is less than 100000Da. The present invention also provides a dimethyl fumarate enteric-coated capsule. The present invention adopts a specific isolation layer coating material, which can realize the coating process at low temperature, thereby effectively inhibiting the sublimation of dimethyl fumarate, reducing raw material loss, and improving the safety and controllability of the production process. The dimethyl fumarate enteric-coated tablets and enteric-coated capsules provided by the present invention have simple prescriptions and compositions, do not require expensive auxiliary materials and reagents, have a simple preparation process, and are suitable for industrial-scale production.

The invention belongs to the technical field of medicines, and particularly relates to a tiopronin composition and a preparation method thereof. The composition is an enteric-coated tablet which is composed of a tablet core and an enteric coating layer, wherein the tablet core contains tiopronin, porous starch, chitosan, vitamin C and other pharmaceutically acceptable filler, adhesive, disintegrating agent and lubricant. The tablet prescription can reduce the impurity content of the preparation product and improve the stability; meanwhile, the dissolution rate of tiopronin is improved; the content is uniform, unpleasant odor is effectively covered, and improvement of patient compliance is facilitated; the preparation method of the composition is simple and suitable for industrial production.

The utility model discloses an efficient dusting machine for enteric-coated tablet production, which relates to the technical field of medicine production and comprises a vehicle body, universal wheels are fixedly mounted below the vehicle body, a handle is fixedly mounted on the side surface of the vehicle body, a baffle is fixedly mounted in the vehicle body, and a negative pressure suction head is detachably mounted at the top of the vehicle body. A guide pipe is fixedly installed at the bottom of the negative pressure suction head, a through hole is formed in the top of the vehicle body, the guide pipe penetrates through the vehicle body, a dust suction pipe is fixedly installed on the left side of the baffle, a pipe hoop is arranged between the dust suction pipe and the guide pipe and is in threaded connection with the dust suction pipe and the guide pipe, the dust suction pipe penetrates through the baffle, and the right side of the baffle is filled with alkali liquor. According to the powder cleaning vehicle, powder in a workshop can be cleaned, the influence of excessive powder in the workshop on the body health of production personnel is avoided, the powder cleaning vehicle is easy and convenient to disassemble and convenient to clean, and the dust removal efficiency is improved.

The invention provides an enteric-coated tablet containing rabeprazole sodium and application of the enteric-coated tablet. The enteric-coated tablet containing rabeprazole sodium comprises a tablet core, an isolating layer and an enteric-coated layer. The applicant directly mixes the rabeprazole sodium and the cimetidine to prepare the enteric-coated tablet for treating peptic ulcer, when the concentration ratio of the rabeprazole sodium to the cimetidine is in a proper range, the treatment effect can be obviously improved compared with that of single rabeprazole sodium treatment, and toxic and side effects are not increased. The compound rabeprazole sodium enteric-coated tablet, which is different from the prior art, is prepared by adopting specific auxiliary materials and selecting a proper ratio, and the compound rabeprazole sodium enteric-coated tablet is relatively good in dissolution performance and high in bioavailability, and has a remarkable clinical value.

To provide a solid preparation that contains lactoferrin and cells of Lacticaseibacillus casei but does not show a decrease in in-vivo collapsibility.SOLUTION: A solid preparation comprising (A) lactoferrin, (B) cells of Lacticaseibacillus casei, and (C) an excipient, where the excipient (C) comprises (C1) at least one of cellulose or a derivative thereof and (C2) at least one sugar alcohol.SELECTED DRAWING: None